Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy

Cyclin-dependent kinase 9 (CDK9) plays a vital role in transcription through regulation of short-lived anti-apoptotic genes required for cancer cell survival. Therefore, targeting CDK9 with small molecule inhibitors has emerged as a potential cancer therapy. This article reviews the most recent CDK9...

Descripción completa

Detalles Bibliográficos
Autor principal: Alsfouk, Aisha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919902/
https://www.ncbi.nlm.nih.gov/pubmed/33632038
http://dx.doi.org/10.1080/14756366.2021.1890726
_version_ 1783658203513356288
author Alsfouk, Aisha
author_facet Alsfouk, Aisha
author_sort Alsfouk, Aisha
collection PubMed
description Cyclin-dependent kinase 9 (CDK9) plays a vital role in transcription through regulation of short-lived anti-apoptotic genes required for cancer cell survival. Therefore, targeting CDK9 with small molecule inhibitors has emerged as a potential cancer therapy. This article reviews the most recent CDK9 patent literature (2012–2020) related to small molecule inhibitors in cancer along with their selectivity profile and biological results in preclinical studies.
format Online
Article
Text
id pubmed-7919902
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-79199022021-03-05 Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy Alsfouk, Aisha J Enzyme Inhib Med Chem Review Article Cyclin-dependent kinase 9 (CDK9) plays a vital role in transcription through regulation of short-lived anti-apoptotic genes required for cancer cell survival. Therefore, targeting CDK9 with small molecule inhibitors has emerged as a potential cancer therapy. This article reviews the most recent CDK9 patent literature (2012–2020) related to small molecule inhibitors in cancer along with their selectivity profile and biological results in preclinical studies. Taylor & Francis 2021-02-25 /pmc/articles/PMC7919902/ /pubmed/33632038 http://dx.doi.org/10.1080/14756366.2021.1890726 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Alsfouk, Aisha
Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy
title Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy
title_full Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy
title_fullStr Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy
title_full_unstemmed Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy
title_short Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy
title_sort small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919902/
https://www.ncbi.nlm.nih.gov/pubmed/33632038
http://dx.doi.org/10.1080/14756366.2021.1890726
work_keys_str_mv AT alsfoukaisha smallmoleculeinhibitorsofcyclindependentkinase9forcancertherapy

Ejemplares similares